TYK Medicines, Inc (HKG:2410)

Market Cap	2.75B -62.5%
Revenue (ttm)	n/a
Net Income	-333.58M
EPS	-0.89
Shares Out	384.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,207,500
Open	6.73
Previous Close	6.81
Day's Range	6.73 - 7.29
52-Week Range	5.35 - 25.75
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About TYK Medicines

TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 173
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2410

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 9, 2026

Data Sources Report a data error